Limitation of production of IFN-γ and IL-17 in the CNS is of importance for the beneficial effects of MP, as abundant data confirm the pathogenic role for IFN-γ and IL-17 in autoimmune diseases, although their contribution to the disease process probably depend on the epitope-specificity of encephalitogenic cells [3], localization of the disease process [4] and conditions present during initial exposure to antigen, including the quality/quantity of Toll-like receptor stimulation and type of antigen-presenting cells [15]. Here, IL17A is linked to autoimmune disease.